Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05042102 · ClinicalTrials.gov registry record · Phase 2
Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)
A Phase 2 study of Alcohol Use Disorder, sponsored by VA Connecticut Healthcare System.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT05042102: Recruiting Phase 2 study of Alcohol Use Disorder, sponsored by VA Connecticut Healthcare System.
NCT05042102 is a Phase 2 study of Alcohol Use Disorder that is actively recruiting participants, run by VA Connecticut Healthcare System. The registered enrollment target is 160 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05042102, a Phase 2 study of Alcohol Use Disorder, is actively recruiting participants, sponsored by VA Connecticut Healthcare System.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the project is to evaluate whether donepezil + cognitive remediation therapy is superior to placebo in reducing heavy drinking in patients with alcohol use disorder in a double-blind, placebo-controlled trial.
Primary Outcome
Heavy drinking days as measured by weekly Time Line Follow Back (TLFB)
Conditions Studied
Interventions
- COMBINATION_PRODUCT Donepezil + Cognitive remediation therapy (CRT)
- COMBINATION_PRODUCT Donepezil + Placebo CRT
- COMBINATION_PRODUCT Placebo medication + Cognitive remediation therapy (CRT)
- COMBINATION_PRODUCT Placebo medication + Placebo CRT
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 2 |
What NCT05042102 shows while recruiting
NCT05042102 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 4 interventions - of which Donepezil + Cognitive remediation therapy (CRT) is the first listed.
NCT05042102 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05042102 about?
NCT05042102 is a clinical study titled "Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)". The goal of the project is to evaluate whether donepezil + cognitive remediation therapy is superior to placebo in reducing heavy drinking in patients with alcohol use disorder in a double-blind, placebo-controlled trial.
What is the current status of trial NCT05042102?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2022-08-08. Estimated completion is 2027-05-31.
What conditions does trial NCT05042102 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT05042102?
The interventions under investigation include: Donepezil + Cognitive remediation therapy (CRT) (COMBINATION_PRODUCT), Donepezil + Placebo CRT (COMBINATION_PRODUCT), Placebo medication + Cognitive remediation therapy (CRT) (COMBINATION_PRODUCT), Placebo medication + Placebo CRT (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05042102?
This trial is sponsored by VA Connecticut Healthcare System, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05042102 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05042102's enrollment target sits among peer trials
160 58th of 184 higher than 125 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI